KR20010074495A - 시에이이브이 및 에이치아이브이-1 유전 인자를 함유하는바이러스 키메라 - Google Patents
시에이이브이 및 에이치아이브이-1 유전 인자를 함유하는바이러스 키메라 Download PDFInfo
- Publication number
- KR20010074495A KR20010074495A KR1020007012062A KR20007012062A KR20010074495A KR 20010074495 A KR20010074495 A KR 20010074495A KR 1020007012062 A KR1020007012062 A KR 1020007012062A KR 20007012062 A KR20007012062 A KR 20007012062A KR 20010074495 A KR20010074495 A KR 20010074495A
- Authority
- KR
- South Korea
- Prior art keywords
- hiv
- chiv
- caev
- viral
- polynucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000003612 virological effect Effects 0.000 title claims description 38
- 230000002068 genetic effect Effects 0.000 title description 2
- 241000700605 Viruses Species 0.000 claims abstract description 59
- 230000002163 immunogen Effects 0.000 claims abstract description 43
- 230000028993 immune response Effects 0.000 claims abstract description 42
- 238000000034 method Methods 0.000 claims abstract description 34
- 229960005486 vaccine Drugs 0.000 claims abstract description 33
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 31
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 31
- 239000002157 polynucleotide Substances 0.000 claims abstract description 31
- 241001430294 unidentified retrovirus Species 0.000 claims abstract description 22
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 14
- 238000000338 in vitro Methods 0.000 claims abstract description 10
- 239000003937 drug carrier Substances 0.000 claims abstract description 8
- 230000004936 stimulating effect Effects 0.000 claims abstract description 8
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 5
- 206010014599 encephalitis Diseases 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 91
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 38
- 239000002245 particle Substances 0.000 claims description 24
- 230000001177 retroviral effect Effects 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 10
- 241000288906 Primates Species 0.000 claims description 8
- 108010067390 Viral Proteins Proteins 0.000 claims description 6
- 230000001717 pathogenic effect Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000001963 growth medium Substances 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 claims description 2
- 230000000120 cytopathologic effect Effects 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 30
- 241000283707 Capra Species 0.000 abstract description 14
- 206010003246 arthritis Diseases 0.000 abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 126
- 241000713756 Caprine arthritis encephalitis virus Species 0.000 description 88
- 210000002966 serum Anatomy 0.000 description 19
- 108020004414 DNA Proteins 0.000 description 18
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 238000003757 reverse transcription PCR Methods 0.000 description 15
- 210000002540 macrophage Anatomy 0.000 description 14
- 230000010076 replication Effects 0.000 description 13
- 208000030507 AIDS Diseases 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 12
- 102100034349 Integrase Human genes 0.000 description 11
- 101710149951 Protein Tat Proteins 0.000 description 11
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 108700004027 tat Genes Proteins 0.000 description 11
- 101100421423 Caenorhabditis elegans spl-1 gene Proteins 0.000 description 10
- 241000282564 Macaca fuscata Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108700004030 rev Genes Proteins 0.000 description 10
- 101150098170 tat gene Proteins 0.000 description 10
- 210000001744 T-lymphocyte Anatomy 0.000 description 9
- 101710090322 Truncated surface protein Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000012228 culture supernatant Substances 0.000 description 9
- 238000003780 insertion Methods 0.000 description 9
- 230000037431 insertion Effects 0.000 description 9
- 102100037904 CD9 antigen Human genes 0.000 description 8
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 description 8
- 101710205625 Capsid protein p24 Proteins 0.000 description 8
- 101710177166 Phosphoprotein Proteins 0.000 description 8
- 101710149279 Small delta antigen Proteins 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 208000031886 HIV Infections Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 239000000853 adhesive Substances 0.000 description 7
- 230000001070 adhesive effect Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 108020004705 Codon Proteins 0.000 description 5
- 108700010908 HIV-1 proteins Proteins 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 108091092328 cellular RNA Proteins 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000002054 inoculum Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 101710177291 Gag polyprotein Proteins 0.000 description 4
- 101710125418 Major capsid protein Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000008676 import Effects 0.000 description 4
- 238000010348 incorporation Methods 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 101710132601 Capsid protein Proteins 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 101150098213 rev gene Proteins 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 208000010648 susceptibility to HIV infection Diseases 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 108700026220 vif Genes Proteins 0.000 description 3
- 230000029812 viral genome replication Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 2
- 101100140622 Caprine arthritis encephalitis virus rev gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 241001507252 Japanese monkeys Species 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 230000010530 Virus Neutralization Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 210000003022 colostrum Anatomy 0.000 description 2
- 235000021277 colostrum Nutrition 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 108010089520 pol Gene Products Proteins 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001566 pro-viral effect Effects 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000014621 translational initiation Effects 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- 101150059019 vif gene Proteins 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101100327808 Arabidopsis thaliana EP3 gene Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100027221 CD81 antigen Human genes 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 1
- 108700020134 Human immunodeficiency virus 1 nef Proteins 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101001037768 Plasmodium berghei 58 kDa phosphoprotein Proteins 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000030538 Thecla Species 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 101710201961 Virion infectivity factor Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 101150055766 cat gene Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 229940124541 immunological agent Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002205 phenol-chloroform extraction Methods 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 101150088264 pol gene Proteins 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 229960003127 rabies vaccine Drugs 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940064914 retrovir Drugs 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8365298P | 1998-04-30 | 1998-04-30 | |
| US60/083,652 | 1998-04-30 | ||
| US09/302,171 | 1999-04-29 | ||
| US09/302,171 US6602505B2 (en) | 1998-04-30 | 1999-04-29 | Viral chimeras comprised of CAEV and HIV-1 genetic elements |
| PCT/US1999/006556 WO1999056774A1 (en) | 1998-04-30 | 1999-04-30 | Viral chimeras comprised of caev and hiv-1 genetic elements |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20010074495A true KR20010074495A (ko) | 2001-08-04 |
Family
ID=26769556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020007012062A Withdrawn KR20010074495A (ko) | 1998-04-30 | 1999-04-30 | 시에이이브이 및 에이치아이브이-1 유전 인자를 함유하는바이러스 키메라 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6602505B2 (enExample) |
| EP (1) | EP1073461B1 (enExample) |
| JP (1) | JP2002513546A (enExample) |
| KR (1) | KR20010074495A (enExample) |
| CN (1) | CN100346827C (enExample) |
| AT (1) | ATE284709T1 (enExample) |
| AU (1) | AU766264B2 (enExample) |
| CA (1) | CA2330618C (enExample) |
| DE (1) | DE69922642T2 (enExample) |
| IL (2) | IL139360A0 (enExample) |
| NZ (1) | NZ507942A (enExample) |
| WO (1) | WO1999056774A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6361784B1 (en) * | 2000-09-29 | 2002-03-26 | The Procter & Gamble Company | Soft, flexible disposable wipe with embossing |
| FR2979919B1 (fr) * | 2011-09-12 | 2015-12-11 | Centre Nat Rech Scient | Genomes lentiviraux chimeriques non-integratifs comme vaccins innovants contre vih-1 |
| WO2013126469A1 (en) * | 2012-02-21 | 2013-08-29 | Immunogenetix Therapeutics, Inc. | Chimeric dna vaccine compositions and methods of use |
| RU2017126206A (ru) * | 2014-12-23 | 2019-01-25 | Маргарет Анне БРИМБЛЕ | Аминокислотные и пептидные конъюгаты и направления их использования |
| AU2017223267B2 (en) | 2016-02-26 | 2021-07-22 | Auckland Uniservices Limited | Amino acid and peptide conjugates and conjugation process |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5142025A (en) | 1986-08-01 | 1992-08-25 | Repligen Corporation | Recombinant HTLV-III proteins and uses thereof |
| US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5851813A (en) | 1990-07-12 | 1998-12-22 | President And Fellows Of Harvard College | Primate lentivirus antigenic compositions |
| US5714374A (en) | 1990-09-12 | 1998-02-03 | Rutgers University | Chimeric rhinoviruses |
| US5770428A (en) | 1993-02-17 | 1998-06-23 | Wisconsin Alumni Research Foundation | Chimeric retrovial expression vectors and particles containing a simple retroviral long terminal repeat, BLV or HIV coding regions and cis-acting regulatory sequences, and an RNA translational enhancer with internal ribsome entry site |
| US5561064A (en) | 1994-02-01 | 1996-10-01 | Vical Incorporated | Production of pharmaceutical-grade plasmid DNA |
| FR2721618B1 (fr) | 1994-06-28 | 1996-09-13 | Centre Nat Rech Scient | Fragments d'acide nucléique et fragments peptidiques correspondants issus du génome du virus de l'arthrite et de l'encéphalite caprine (VAEC) et leurs applications. |
| US5955342A (en) | 1994-08-15 | 1999-09-21 | Connaught Laboratories Limited | Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region |
| FR2732346B1 (fr) | 1995-03-27 | 1997-05-30 | Centre Nat Rech Scient | Proteines mutees, codees par un gene env mute de lentivirus, fragments peptidiques inclus dans lesdites proteines, vecteurs d'expression exprimant lesdites proteines mutees et leurs applications |
| DE69707680T2 (de) | 1996-03-15 | 2002-07-11 | University Of Southern California, Los Angeles | Caprin arthritis-enzephalitis virus enthaltende vakzine und verwendung zur immunschutz gegen hiv-1 infektion |
| US5770357A (en) | 1996-03-15 | 1998-06-23 | Univ Southern California | Method of diagnosing caprine arthritis-encephalitis virus infection |
| EP1012236A1 (en) * | 1997-08-15 | 2000-06-28 | Rubicon Laboratory Inc. | Retrovirus and viral vectors |
-
1999
- 1999-04-29 US US09/302,171 patent/US6602505B2/en not_active Expired - Lifetime
- 1999-04-30 AT AT99919756T patent/ATE284709T1/de not_active IP Right Cessation
- 1999-04-30 AU AU37406/99A patent/AU766264B2/en not_active Ceased
- 1999-04-30 DE DE69922642T patent/DE69922642T2/de not_active Expired - Lifetime
- 1999-04-30 NZ NZ507942A patent/NZ507942A/xx not_active IP Right Cessation
- 1999-04-30 KR KR1020007012062A patent/KR20010074495A/ko not_active Withdrawn
- 1999-04-30 IL IL13936099A patent/IL139360A0/xx active IP Right Grant
- 1999-04-30 WO PCT/US1999/006556 patent/WO1999056774A1/en not_active Ceased
- 1999-04-30 JP JP2000546798A patent/JP2002513546A/ja active Pending
- 1999-04-30 EP EP99919756A patent/EP1073461B1/en not_active Expired - Lifetime
- 1999-04-30 CA CA2330618A patent/CA2330618C/en not_active Expired - Fee Related
- 1999-04-30 CN CNB99807912XA patent/CN100346827C/zh not_active Expired - Fee Related
-
2000
- 2000-10-30 IL IL139360A patent/IL139360A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE284709T1 (de) | 2005-01-15 |
| US20010039669A1 (en) | 2001-11-08 |
| EP1073461A1 (en) | 2001-02-07 |
| JP2002513546A (ja) | 2002-05-14 |
| NZ507942A (en) | 2003-06-30 |
| EP1073461B1 (en) | 2004-12-15 |
| WO1999056774A1 (en) | 1999-11-11 |
| CA2330618A1 (en) | 1999-11-11 |
| CN1311689A (zh) | 2001-09-05 |
| DE69922642D1 (de) | 2005-01-20 |
| US6602505B2 (en) | 2003-08-05 |
| IL139360A0 (en) | 2001-11-25 |
| AU766264B2 (en) | 2003-10-09 |
| EP1073461A4 (en) | 2002-03-20 |
| DE69922642T2 (de) | 2005-12-22 |
| CA2330618C (en) | 2012-07-03 |
| IL139360A (en) | 2007-07-24 |
| AU3740699A (en) | 1999-11-23 |
| CN100346827C (zh) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12370253B2 (en) | Pre-immunization and immunotherapy | |
| US12090200B2 (en) | Methods of producing cells resistant to HIV infection | |
| JP3881689B2 (ja) | 免疫不全ウイルス用の遺伝子ワクチン | |
| JP3871708B2 (ja) | 抗原的に標識した非感染性レトロウィルス様粒子 | |
| KR19990081931A (ko) | Hiv 에 대한 폴리엔브 백신으로서 재조합 백시니아 벡터의혼합물 | |
| Miyake et al. | Induction of HIV‐specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV‐capturing nanospheres in macaques | |
| JPH08500965A (ja) | ハイブリッドウイルス発現ベクター，その使用および新規アッセイ | |
| JPH1059868A (ja) | Ａｉｄｓの原因ウィルスの糖蛋白質からなるワクチン | |
| DE69124215T2 (de) | Primaten-lentivirus impfstoffe | |
| GARDNER | Vaccination against SIV infection and disease | |
| Narayan et al. | Characterization of a neutralization-escape variant of SHIVKU-1, a virus that causes acquired immune deficiency syndrome in pig-tailed macaques | |
| US9879230B2 (en) | Chimeric non-integrating lentiviral genomes as vaccines against HIV-1 | |
| KR20010074495A (ko) | 시에이이브이 및 에이치아이브이-1 유전 인자를 함유하는바이러스 키메라 | |
| JP2003535577A (ja) | 免疫不全ウイルス用生ウイルスワクチンとしての組換えラブドウイルス | |
| DE69707680T2 (de) | Caprin arthritis-enzephalitis virus enthaltende vakzine und verwendung zur immunschutz gegen hiv-1 infektion | |
| Enose et al. | Restriction of viral population by intravaginal infection of simian immunodeficiency viruses in macaque monkeys | |
| Velarde de la Cruz et al. | Oral vaccination approaches for Anti-SHIV immunity | |
| ZA200006314B (en) | Viral chimeras comprised of CAEV and HIV-1 genetic elements. | |
| MXPA00010701A (es) | Quimeras virales comprendidas por elementos geneticos de hiv-1 y caev | |
| Karlsson et al. | Jellis, AT Profy, JR Rusche, DP Bolognesi, SD Putney, and TJ Matthews. 1989. Principal ncutralizing domain of the lhuman immunodcfi-cicncy virus typc 1 cnvclopc protcin. Proc. Natl. Acad. Sci. USA 86: 6768– | |
| FR2593519A1 (fr) | Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin | |
| JP2001328946A (ja) | 免疫不全ウイルスワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20001030 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |